Chardan Capital Reaffirms Neutral Rating for Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “neutral” rating reaffirmed by investment analysts at Chardan Capital in a research report issued to clients and investors on Monday, MarketBeat reports.

A number of other equities research analysts also recently commented on OTLK. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research report on Friday, November 29th. BTIG Research reduced their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Finally, Ascendiant Capital Markets lowered their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.34.

Outlook Therapeutics Stock Performance

OTLK stock opened at $1.80 on Monday. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The firm has a market cap of $42.59 million, a PE ratio of -0.17 and a beta of 0.46. The firm’s 50 day moving average price is $5.14 and its 200-day moving average price is $6.62.

Insiders Place Their Bets

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the acquisition, the chief financial officer now owns 5,946 shares of the company’s stock, valued at approximately $33,832.74. This trade represents a 528.54 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Outlook Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OTLK. Great Point Partners LLC increased its position in shares of Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after acquiring an additional 221,510 shares during the period. Rosalind Advisors Inc. grew its stake in Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after purchasing an additional 138,225 shares in the last quarter. Geode Capital Management LLC increased its holdings in Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after purchasing an additional 112,812 shares during the period. LVW Advisors LLC acquired a new stake in Outlook Therapeutics in the 2nd quarter valued at about $352,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Outlook Therapeutics in the 2nd quarter valued at about $303,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.